182 related articles for article (PubMed ID: 31092557)
1. The PHLPP2 phosphatase is a druggable driver of prostate cancer progression.
Nowak DG; Katsenelson KC; Watrud KE; Chen M; Mathew G; D'Andrea VD; Lee MF; Swamynathan MM; Casanova-Salas I; Jibilian MC; Buckholtz CL; Ambrico AJ; Pan CH; Wilkinson JE; Newton AC; Trotman LC
J Cell Biol; 2019 Jun; 218(6):1943-1957. PubMed ID: 31092557
[TBL] [Abstract][Full Text] [Related]
2. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.
Nowak DG; Cho H; Herzka T; Watrud K; DeMarco DV; Wang VM; Senturk S; Fellmann C; Ding D; Beinortas T; Kleinman D; Chen M; Sordella R; Wilkinson JE; Castillo-Martin M; Cordon-Cardo C; Robinson BD; Trotman LC
Cancer Discov; 2015 Jun; 5(6):636-51. PubMed ID: 25829425
[TBL] [Abstract][Full Text] [Related]
3. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis.
Cho H; Herzka T; Zheng W; Qi J; Wilkinson JE; Bradner JE; Robinson BD; Castillo-Martin M; Cordon-Cardo C; Trotman LC
Cancer Discov; 2014 Mar; 4(3):318-33. PubMed ID: 24444712
[TBL] [Abstract][Full Text] [Related]
4. A balancing act: PHLPP2 fine tunes AKT activity and MYC stability in prostate cancer.
Toivanen R; Furic L
J Cell Biol; 2019 Jun; 218(6):1771-1772. PubMed ID: 31145683
[TBL] [Abstract][Full Text] [Related]
5. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression.
Chen M; Pratt CP; Zeeman ME; Schultz N; Taylor BS; O'Neill A; Castillo-Martin M; Nowak DG; Naguib A; Grace DM; Murn J; Navin N; Atwal GS; Sander C; Gerald WL; Cordon-Cardo C; Newton AC; Carver BS; Trotman LC
Cancer Cell; 2011 Aug; 20(2):173-86. PubMed ID: 21840483
[TBL] [Abstract][Full Text] [Related]
6. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
7. Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer.
Kim J; Eltoum IE; Roh M; Wang J; Abdulkadir SA
PLoS Genet; 2009 Jul; 5(7):e1000542. PubMed ID: 19578399
[TBL] [Abstract][Full Text] [Related]
8. PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma.
Molina JR; Agarwal NK; Morales FC; Hayashi Y; Aldape KD; Cote G; Georgescu MM
Oncogene; 2012 Mar; 31(10):1264-74. PubMed ID: 21804599
[TBL] [Abstract][Full Text] [Related]
9. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice.
Narayanan NK; Nargi D; Randolph C; Narayanan BA
Int J Cancer; 2009 Jul; 125(1):1-8. PubMed ID: 19326431
[TBL] [Abstract][Full Text] [Related]
10. PTP1B Deficiency Enables the Ability of a High-Fat Diet to Drive the Invasive Character of PTEN-Deficient Prostate Cancers.
Labbé DP; Uetani N; Vinette V; Lessard L; Aubry I; Migon E; Sirois J; Haigh JJ; Bégin LR; Trotman LC; Paquet M; Tremblay ML
Cancer Res; 2016 Jun; 76(11):3130-5. PubMed ID: 27020859
[TBL] [Abstract][Full Text] [Related]
11. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
[TBL] [Abstract][Full Text] [Related]
12. Rapid in vivo validation of candidate drivers derived from the PTEN-mutant prostate metastasis genome.
Cho H; Herzka T; Stahlhut C; Watrud K; Robinson BD; Trotman LC
Methods; 2015 May; 77-78():197-204. PubMed ID: 25592467
[TBL] [Abstract][Full Text] [Related]
13. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.
Kim J; Roh M; Doubinskaia I; Algarroba GN; Eltoum IE; Abdulkadir SA
Oncogene; 2012 Jan; 31(3):322-32. PubMed ID: 21685943
[TBL] [Abstract][Full Text] [Related]
14. CXADR-Mediated Formation of an AKT Inhibitory Signalosome at Tight Junctions Controls Epithelial-Mesenchymal Plasticity in Breast Cancer.
Nilchian A; Johansson J; Ghalali A; Asanin ST; Santiago A; Rosencrantz O; Sollerbrant K; Vincent CT; Sund M; Stenius U; Fuxe J
Cancer Res; 2019 Jan; 79(1):47-60. PubMed ID: 30385615
[TBL] [Abstract][Full Text] [Related]
15. An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal.
Salah M; Nishimoto Y; Kohno S; Kondoh A; Kitajima S; Muranaka H; Nishiuchi T; Ibrahim A; Yoshida A; Takahashi C
Mol Carcinog; 2016 Dec; 55(12):1974-1989. PubMed ID: 26621780
[TBL] [Abstract][Full Text] [Related]
16. Endothelial Scaffolding Protein ENH (Enigma Homolog Protein) Promotes PHLPP2 (Pleckstrin Homology Domain and Leucine-Rich Repeat Protein Phosphatase 2)-Mediated Dephosphorylation of AKT1 and eNOS (Endothelial NO Synthase) Promoting Vascular Remodeling.
Huang J; Cai C; Zheng T; Wu X; Wang D; Zhang K; Xu B; Yan R; Gong H; Zhang J; Shi Y; Xu Z; Zhang X; Zhang X; Shang T; Zhou J; Guo X; Zeng C; Lai EY; Xiao C; Chen J; Wan S; Liu WH; Ke Y; Cheng H
Arterioscler Thromb Vasc Biol; 2020 Jul; 40(7):1705-1721. PubMed ID: 32268790
[TBL] [Abstract][Full Text] [Related]
17. Loss of FOXP3 and TSC1 Accelerates Prostate Cancer Progression through Synergistic Transcriptional and Posttranslational Regulation of c-MYC.
Wu L; Yi B; Wei S; Rao D; He Y; Naik G; Bae S; Liu XM; Yang WH; Sonpavde G; Liu R; Wang L
Cancer Res; 2019 Apr; 79(7):1413-1425. PubMed ID: 30733194
[TBL] [Abstract][Full Text] [Related]
18. R1 Regulates Prostate Tumor Growth and Progression By Transcriptional Suppression of the E3 Ligase HUWE1 to Stabilize c-Myc.
Lin TP; Li J; Li Q; Li X; Liu C; Zeng N; Huang JM; Chu GC; Lin CH; Zhau HE; Chung LWK; Wu BJ; Shih JC
Mol Cancer Res; 2018 Dec; 16(12):1940-1951. PubMed ID: 30042175
[TBL] [Abstract][Full Text] [Related]
19. Turning off AKT: PHLPP as a drug target.
Newton AC; Trotman LC
Annu Rev Pharmacol Toxicol; 2014; 54():537-58. PubMed ID: 24392697
[TBL] [Abstract][Full Text] [Related]
20. Pten dose dictates cancer progression in the prostate.
Trotman LC; Niki M; Dotan ZA; Koutcher JA; Di Cristofano A; Xiao A; Khoo AS; Roy-Burman P; Greenberg NM; Van Dyke T; Cordon-Cardo C; Pandolfi PP
PLoS Biol; 2003 Dec; 1(3):E59. PubMed ID: 14691534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
